CORC

在结果中检索

CORC

浏览/检索结果: 共59条，第1-10条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: Efficacy and safety analysis of a randomized phase III study in Asian patients (PEONY) 会议论文
作者:  Zhou, J.;  Eng-Wong, J.;  Mao, Y.;  Althaus, B.;  Liao, N.
收藏  |  浏览/下载：12/0  |  提交时间：2019/12/05
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study 会议论文
作者:  Wu, Yi-Long;  Lu, Shun;  Cheng, Ying;  Zhou, Caicun;  Wang, Jie
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05
CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC) 会议论文
作者:  Wu, Y.;  Chang, J.;  Zhang, L.;  Tu, H.;  Wu, L.
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05
Trastuzumab plus docetaxel and capecitabine for first-line treatment of Her2-positive advanced gastric cancer: A phase II, multi-center, open-label, singlearm study. 会议论文
作者:  Wang, Feng;  Liu, Tian Shu;  Yuan, Xianglin;  Gu, Kangsheng;  Yuan, Ying
收藏  |  浏览/下载：9/0  |  提交时间：2019/12/05
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer (NSCLC): results of the phase 3 CheckMate 078 study 会议论文
CANCER RESEARCH, 2018-07-01
作者:  Wu, Yi-Long;  Lu, Shun;  Cheng, Ying;  Zhou, Caicun;  Wang, Jie
收藏  |  浏览/下载：3/0  |  提交时间：2020/01/03
EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs) 会议论文
作者:  Soo, R.;  Mok, T. S. K.;  Shi, Y-K.;  Zhang, L.;  Lu, S.
收藏  |  浏览/下载：33/0  |  提交时间：2019/12/05
Real-world use of docetaxel for metastatic castration-resistant prostate cancer in China: Results from a large observational study 会议论文
作者:  He, D.;  Sun, Z.;  Guo, J.;  Zhang, Z.;  Shan, Y.
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/05
Real-world use of docetaxel for metastatic castration-resistant prostate cancer in China: Results from a large observational study 会议论文
作者:  He, D.;  Sun, Z.;  Guo, J.;  Zhang, Z.;  Shan, Y.
收藏  |  浏览/下载：3/0  |  提交时间：2019/11/26
EAST-LC: Randomized controlled phase III trial of S-1 versus docetaxel (DOC) in patients with non-small cell lung cancer (NSCLC) who had received a platinum-based treatment: Results from patient-reported outcomes (PROs) 会议论文
ANNALS OF ONCOLOGY, 2017-11-01
作者:  Soo, R.;  Mok, T. S. K.;  Shi, Y-K.;  Zhang, L.;  Lu, S.
收藏  |  浏览/下载：28/0  |  提交时间：2020/01/04
The preliminary study of 18F-FES PET/CT in predicting postmenopausal patients with ER/PR plus , metastatic breast cancer receiving combination treatment of fulvestrant and docetaxel 会议论文
作者:  Yang, Z.;  Sun, Y.;  Zhang, J.;  Wang, B.;  He, S.
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace